BIO-TECHNE Corp TECH

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation ("Bio-Techne", "we", "our", "us" or the "Company"), develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. Our broad product portfolio and application expertise enables scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

We manage the business in two operating segments – our Protein Sciences segment and our Diagnostics and Spatial Biology segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for protein analysis, automated western blot, and multiplexed ELISA workflows. Our Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications.

Last close 72.55 2026-10-23
Market cap $11.38B 2026-06-30 share count
52-week range 43.20 - 72.69

Valuation FY2026 figures against the last close

P/S9.4x
P/E62.5x
P/FCF43.2x
EV/EBITDA32.6x
Dividend yield0.4%
Diluted EPS1.16

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • EMEA, excluding United Kingdom
  • Greater China
  • APAC, excluding Greater China
  • United Kingdom
  • Rest of World
Revenue by geography, 6 categories over 3 years. The same figures are in the table below. FY2026 United States, FY2026: 635.4M (52.3%) 52% United States EMEA, excluding United Kingdom, FY2026: 294.2M (24.2%) 24% EMEA, excluding United Kingdom Greater China, FY2026: 104.1M (8.6%) 9% APAC, excluding Greater China, FY2026: 85.8M (7.1%) 7% United Kingdom, FY2026: 56.3M (4.6%) 5% Rest of World, FY2026: 39.3M (3.2%) FY2025 United States, FY2025: 683.2M (56.0%) 56% EMEA, excluding United Kingdom, FY2025: 266.3M (21.8%) 22% Greater China, FY2025: 100.5M (8.2%) 8% APAC, excluding Greater China, FY2025: 77.3M (6.3%) 6% United Kingdom, FY2025: 54.8M (4.5%) 4% Rest of World, FY2025: 37.5M (3.1%) FY2024 United States, FY2024: 657.7M (56.7%) 57% EMEA, excluding United Kingdom, FY2024: 241.4M (20.8%) 21% Greater China, FY2024: 99.5M (8.6%) 9% APAC, excluding Greater China, FY2024: 73.9M (6.4%) 6% United Kingdom, FY2024: 50M (4.3%) 4% Rest of World, FY2024: 36.5M (3.1%)
Region FY2026FY2025FY2024
United States $635.4M $683.2M $657.7M
EMEA, excluding United Kingdom $294.2M $266.3M $241.4M
Greater China $104.1M $100.5M $99.5M
APAC, excluding Greater China $85.8M $77.3M $73.9M
United Kingdom $56.3M $54.8M $50.0M
Rest of World $39.3M $37.5M $36.5M

As the company reported it, from the “Revenue Recognition - Disaggregation of Revenue (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $1.22B$1.22B$1.16B$1.14B$1.11B$931.0M$738.7M$714.0M$643.0M$563.0M
Cost of revenue $416.0M$429.4M$389.3M$366.9M$349.1M$298.2M$255.5M$240.5M$210.8M$188.5M
Gross profit $799.1M$790.3M$769.7M$769.8M$756.5M$632.9M$483.2M$473.5M$432.1M$374.5M
SG&A $452.4M$588.5M$466.4M$378.4M$372.8M$325.0M$260.6M$264.4M$240.6M$200.4M
Total operating expenses $547.2M$688.0M$563.0M$470.9M$459.9M$395.6M$325.8M$326.8M$296.0M$254.0M
Operating income $251.9M$102.3M$206.7M$298.9M$296.6M$237.3M$157.4M$146.7M$136.2M$120.6M
Interest expense $9.6M$8.5M$15.7M$11.2M$11.3M$14.0M$19.2M$21.7M$10.2M$7.4M
Pre-tax income $240.7M$98.5M$185.7M$338.7M$301.4M$148.2M$276.5M$112.0M$126.0M$112.0M
Income tax $58.8M$25.1M$17.6M$53.2M$38.3M$8.6M$47.2M$15.9M$198.0K$35.9M
Net income $181.9M$73.4M$168.1M$285.3M$272.1M$140.4M$229.3M$96.1M$126.2M$76.1M
EPS, basic 1.170.471.071.811.730.916.002.543.362.04
EPS, diluted 1.160.461.051.761.660.875.822.473.312.03
Shares, diluted (wtd. avg.) 157.0M159.7M160.8M161.9M164.1M161.9M39.4M38.9M38.1M37.5M

Balance sheet

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $264.7M$162.2M$151.8M$180.6M$172.6M$199.1M$146.6M$100.9M$122.0M$91.6M
Short-term investments ——$1.1M$23.7M$74.5M$32.5M————
Receivables $216.6M$206.9M$241.4M$218.5M$194.5M$145.4M$122.5M$137.5M$120.3M$116.8M
Inventory $195.7M$189.4M$179.7M$171.6M$141.1M$116.7M$103.2M$91.0M$85.6M$60.2M
Total current assets $744.4M$608.3M$617.4M$621.5M$605.6M$510.6M$520.9M$412.6M$398.4M$348.0M
Property, plant and equipment $231.8M$245.7M$251.2M$226.2M$223.2M$207.9M$176.8M$154.0M$145.3M$135.1M
Goodwill $975.4M$980.9M$972.7M$872.7M$822.1M$843.1M$728.3M$732.7M$597.9M$579.0M
Other intangibles $303.5M$365.6M$507.1M$534.6M$531.5M$616.0M$516.5M$579.4M$446.3M$452.0M
Total assets $2.59B$2.56B$2.70B$2.64B$2.29B$2.26B$2.03B$1.88B$1.59B$1.56B
Accounts payable $26.7M$25.3M$38.0M$25.7M$33.9M$29.4M$23.1M$16.2M$18.5M$16.9M
Short-term debt ————$12.5M$12.5M$12.5M$12.5M——
Total current liabilities $163.7M$175.8M$159.4M$128.5M$176.0M$152.3M$106.7M$102.0M$79.5M$135.5M
Retained earnings $1.14B$1.07B$1.33B$1.31B$1.12B$1.09B$1.06B$931.9M$876.9M$799.0M
Total equity $2.11B$1.92B$2.07B$1.97B$1.70B$1.57B$1.38B$1.17B$1.08B$949.6M

Cash flow

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $292.1M$287.6M$299.0M$254.4M$325.3M$352.2M$205.2M$181.6M$170.4M$143.7M
Depreciation and amortisation $97.4M$109.9M$111.7M$107.2M$101.1M$87.7M$82.7M$78.2M$64.5M$60.0M
Stock-based compensation $41.4M$40.8M$38.0M$39.2M$42.2M$49.0M$32.4M$32.3M$28.2M$14.6M
Capital expenditure $28.9M$31.0M$62.9M$38.2M$44.9M$44.3M$51.7M$25.4M$20.9M$15.2M
Investing cash flow -$18.2M-$35.2M-$203.0M-$265.6M-$96.9M-$243.5M$27.1M-$336.8M-$38.7M-$306.0M
Financing cash flow -$169.1M-$253.9M-$122.4M$22.6M-$242.9M-$62.6M-$183.8M$134.4M-$99.2M$189.1M
Dividends paid $49.9M$50.4M$50.4M$50.3M$50.2M$49.6M$48.9M$48.4M$48.0M$47.3M
Buybacks $41.7M$275.7M$80.0M$19.6M$160.9M$43.2M$50.1M$15.4M$0—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-100322.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 500M 1B 1.5B Revenue, FY2017: 563M Gross profit, FY2017: 374.5M Net income, FY2017: 76.1M Revenue, FY2018: 643M Gross profit, FY2018: 432.1M Net income, FY2018: 126.2M Revenue, FY2019: 714M Gross profit, FY2019: 473.5M Net income, FY2019: 96.1M Revenue, FY2020: 738.7M Gross profit, FY2020: 483.2M Net income, FY2020: 229.3M Revenue, FY2021: 931M Gross profit, FY2021: 632.9M Net income, FY2021: 140.4M Revenue, FY2022: 1.1B Gross profit, FY2022: 756.5M Net income, FY2022: 272.1M Revenue, FY2023: 1.1B Gross profit, FY2023: 769.8M Net income, FY2023: 285.3M Revenue, FY2024: 1.2B Gross profit, FY2024: 769.7M Net income, FY2024: 168.1M Revenue, FY2025: 1.2B Gross profit, FY2025: 790.3M Net income, FY2025: 73.4M Revenue, FY2026: 1.2B Gross profit, FY2026: 799.1M Net income, FY2026: 181.9M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue $563.0M $643.0M $714.0M $738.7M $931.0M $1.11B $1.14B $1.16B $1.22B $1.22B
Gross profit $374.5M $432.1M $473.5M $483.2M $632.9M $756.5M $769.8M $769.7M $790.3M $799.1M
Net income $76.1M $126.2M $96.1M $229.3M $140.4M $272.1M $285.3M $168.1M $73.4M $181.9M

Recent filings and events

  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Other event Item 8.01
  • Officer or director change Item 5.02
  • Other event Item 8.01
  • Results announced Item 2.02
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%